These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 3713372)

  • 1. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Heymer B; Finger H; Wirsing CH
    Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.
    Phillips NC; Tsao MS
    Cancer Res; 1989 Feb; 49(4):936-9. PubMed ID: 2912563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
    Ishihara C; Yamamoto K; Hamada N; Azuma I
    Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
    Nagao S; Sato K; Osada Y
    Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune response to Bacteroides gingivalis fimbrial antigen in mice.
    Ogawa T; Shimauchi H; Kusumoto Y; Hamada S
    Immunology; 1990 Jan; 69(1):8-13. PubMed ID: 1968885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
    Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
    J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
    Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
    J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposite effects of the synthetic adjuvant N-acetyl-muramyl-L-alanyl-D-isoglutamine on the immune response in mice depending on experimental conditions.
    Souvannavong V; Adam A
    Eur J Immunol; 1980 Aug; 10(8):654-6. PubMed ID: 6995138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
    Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
    Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of colony-stimulating activity in mice by injection of liposomes containing lipophilic muramyl peptide derivatives.
    Galelli A; Charlot B; Phillips NC; Chedid L
    Cancer Res; 1989 Feb; 49(4):810-5. PubMed ID: 2783556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutagenicity studies of muroctasin.
    Shimada H; Hattori C; Sato T
    Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic influences on the adjuvanticity of muramyl dipeptide in vivo.
    Staruch MJ; Wood DD
    J Immunol; 1982 Jan; 128(1):155-60. PubMed ID: 6976368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunoadjuvant activity of lipophilic derivatives of N-acetylglucosaminyl-beta(1-->4)-N-acetylmuramyl-L-alanyl-D-isoglutamin yl-(L)- 2,6-meso-diaminopimeric acid-(D)-amide.
    Ogawa T; Shimauchi H; Furuta R; Kawata S; Yokogawa K; Kotani S
    Vaccine; 1995 Jul; 13(10):887-9. PubMed ID: 7483759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of immune responses by muroctasin.
    Akasaki M
    Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo augmentation by muroctasin of the production of the third component of complement by murine macrophages.
    Endo N
    Arzneimittelforschung; 1988 Jul; 38(7A):993-6. PubMed ID: 3190805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.